



## Ivermectin + Therapeutics Changes for Outpatient Treatment of Mild to Moderate COVID-19

On February 1, 2022, the CDC shared the following COCA Now: [Ivermectin Products are Not Approved by FDA to Prevent or Treat COVID-19](#). Clinicians should be aware of the symptoms associated with ivermectin overdose, including:

- **Gastrointestinal symptoms** such as nausea, vomiting, and diarrhea
- **Low blood pressure**
- **Neurologic effects** such as decreased consciousness, confusion, hallucinations, central nervous system depression, seizures, coma, and death

Ivermectin may also increase sedative effects of other medications such as benzodiazepines and barbiturates.

On February 2, 2022, CDPH released the attached CaHAN (*Omicron Variant Update: Therapeutics Changes for Outpatient Treatment of Mild to Moderate COVID-19*), summarized as follows:

Two of the anti-SARS-CoV-2 monoclonal antibody products that have received Emergency Use Authorizations (EUAs) from the US Food and Drug Administration (FDA), **bamlanivimab/etesevimab** and **casirivimab/imdevimab (REGEN-COV)**, are not effective against the Omicron variant and are *no longer authorized* for use as a treatment or as a post-exposure prophylaxis (PEP) for use in any U.S. state, territory, or jurisdiction as of January 24, 2022. The anti-SARS-CoV-2 monoclonal antibody **Sotrovimab** is expected to retain activity against Omicron. **Remdesivir (Veklury)** has recently received FDA approval for outpatient treatment of mild to moderate COVID-19 disease and is active against the Omicron variant. Both FDA authorized oral anti-viral agents, ritonavir-boosted nirmatrelvir (**Paxlovid**) and **molnupiravir**, are effective against the Omicron variant. Supply of the most effective therapeutic options against Omicron currently remain limited, so CDPH recommends focusing on treating outpatients meeting NIH tier 1 and 2 criteria.

**For questions regarding the distribution of COVID-19 outpatient therapeutic products within ALCO**, please contact Cynthia Frankel, RN, Alameda County Therapeutics Distribution Lead at [cynthia.frankel@acgov.org](mailto:cynthia.frankel@acgov.org)

**For clinical questions about COVID-19 therapeutics**, please contact Arnie Spanjers, MD, Alameda County Public Health Department at [arnie.spanjers@acgov.org](mailto:arnie.spanjers@acgov.org)